Meagan Gray

2930-LB: Implementation of FIB-4 Alerts in EHRs to Increase Screening for Liver Disease

Sai Sumedha Bobba, Jeevan Nammi, Kristi Cohn, Meagan Gray et autres

Introduction and Objective: Recent ADA guidance recommends screening individuals with T2D for liver fibrosis with FIB-4 index followed by confirmatory testing. However, implementation of these recommendations remains low. This project assessed whether an electronic health record (EHR) alert for elevated FIB-4 improved …

us (code pays fourni par la source)

Global Longitudinal Assessment of MASLD Using Magnetic Resonance Elastography ( GOLDMINE ): A Multi‐Center, International Prospective Cohort Study of Imaging Biomarkers in MASLD Clinical Outcomes

Suzanne R. Sharpton, Luis Antonio Diaz, Kay Pepin, Maral Amangurbanova et autres

BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) exhibits marked heterogeneity in fibrosis progression and liver-related outcomes. Liver biopsy is not feasible for longitudinal risk stratification at scale, creating a need for validated non-invasive biomarkers, particularly imaging biomarkers, that can predict clinically meaningful …

us, cl, jp, fr, sg, fi, es (code pays fourni par la source)

Screening for Hepatocellular Carcinoma Recurrence After Liver Transplantation: Prospective Validation of Binary Criteria

Wesley Dixon, Shaun Chandna, Jordan Sack, Meagan Gray et autres

BACKGROUND: Many centers screen all recipients for hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT). This approach may add substantial burdens of cost, incidental findings, and, depending on the imaging modality, radiation and/or contrast-induced complications. We created simple criteria to help clinicians …

us (code pays fourni par la source)

The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists

Naim Alkhouri, Michael Charlton, Meagan Gray, Mazen Noureddin

INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1RAs), and dual GLP-1/glucose-dependent insulinotropic peptide (GIP) or glucagon receptor agonists have emerged as promising agents to treat metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH). Although the beneficial effects of GLP-1RAs on glycemic control and …

us (code pays fourni par la source)

Larsucosterol for the Treatment of Alcohol-Associated Hepatitis

Mitchell Shiffman, Ben L. Da, Aparna Goel, Allison J. Kwong et autres

BACKGROUND: Larsucosterol is a DNA methyltransferase inhibitor in development for alcohol-associated hepatitis (AH), a disease for which there is no approved therapy. METHODS: In this phase 2b trial, patients with severe AH were randomly assigned 1:1:1 to receive 30 mg or 90 …

us, be, au, ph, gb (code pays fourni par la source)

S4320 The Last Resort: A Case of Relapsing Autoimmune Hepatitis Responsive to Cyclophosphamide Salvage Therapy

Ethan D. Pollack, José León De La Rocha, Meagan Gray, Fatme Ghandour et autres

Introduction: Management of autoimmune hepatitis (AIH) is challenging for patients who either fail to respond or experience adverse effects with first line therapies. Existing literature is limited and demonstrates variable efficacy for salvage therapies. Here, we present a case of refractory AIH …

us (code pays fourni par la source)

S4427 Drug-Induced Autoimmune-Like Hepatitis and Stevens Johnsons Syndrome Secondary to Levetiracetam

Dalton M. Caviness, Kristin M. Olson, Meagan Gray

Introduction: Drug-induced liver injury (DILI) is common and can mimic both acute and chronic liver disease. A subset of patients with DILI will have drug induced autoimmune-like hepatitis (DI-ALH), which can present at any time during the course of treatment. DI-ALH is …

us (code pays fourni par la source)

Metabolic characteristics of patients with MetALD : Caveats of a new definition

Erin Petrie, Meagan Gray, Fernando Bril

BACKGROUND AND AIMS: Recently, a new entity was introduced, MetALD, which includes patients with metabolic dysfunction-associated steatotic liver disease (MASLD), who consume moderate amounts of alcohol. However, little is known regarding the metabolic and clinical characteristics of these patients. METHODS: Data from …

us (code pays fourni par la source)

Harmonized multi-site MRI-based quantification of human liver fat and stiffness: a pilot study

Maninder Singh, Owen Carmichael, Adil Bashir, Anne Russel et autres

Non-alcoholic fatty liver disease (NAFLD) is a leading cause of end-stage liver disease. NAFLD diagnosis and follow-up relies on a combination of clinical data, liver imaging, and/or liver biopsy. However, inter-site imaging differences impede diagnostic consistency and reduce the repeatability of the …

Fazirsiran for Adults With Alpha-1 Antitrypsin Deficiency Liver Disease: A Phase 2 Placebo Controlled Trial (SEQUOIA)

Virginia Clark, Charlie Strange, Pavel Strnad, Antonio J. Sanchez et autres

BACKGROUND & AIMS: Homozygous ZZ alpha-1 antitrypsin (AAT) deficiency produces mutant AAT (Z-AAT) proteins in hepatocytes, leading to progressive liver fibrosis. We evaluated the safety and efficacy of an investigational RNA interference therapeutic, fazirsiran, that degrades Z-AAT messenger RNA, reducing deleterious protein …

us, de, pt, nl, it, es (code pays fourni par la source)

1988-LB: Effects of Alcohol Consumption among Patients with Hepatic Steatosis and Prediabetes or Diabetes

Sravani Bantu, Erin Petrie, Meagan Gray, FERNANDO BRIL

In December of 2023, a multisociety Delphi consensus on fatty liver disease nomenclature was published renaming nonalcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic liver disease (MASLD) and introduced the term MetALD, which identifies patients with MASLD, who also are moderate …

us (code pays fourni par la source)

LBO-003 Results of a phase 2b multicenter randomized trial of larsucosterol for the treatment of severe alcohol-associated hepatitis (AHFIRM trial)

Mitchell Shiffman, Ben L. Da, Lance L. Stein, Christophe Moreno et autres